论文部分内容阅读
目的:比较恩替卡韦和拉夫米定治疗乙肝的疗效,寻求更好的乙肝治疗方法。方法:将我院入住的乙肝患者60例纳入研究对象之中,按照随机原则将患者分为恩替卡韦组和拉夫米定组。拉夫米定治疗组患者在此基础上予以拉夫米定口服治疗,恩替卡韦治疗组患者在此基础上予以恩替卡韦口服治疗,比较两组患者治疗16周、32周、64周后的ALT恢复正常、抗肝纤维化指标恢复情况和Child-Pugh肝功能评分分级情况,使用spss15.0统计软件对以上数据进行分析,综合评定两组患者的治疗效果。结果:两组患者治疗16周、32周、64周后,肝功能各指标较治疗前得到明显的改善,但恩替卡韦组的肝功能改善情况显著优于拉夫米定组,经SPSS15.0软件分析后χ2检验值分别为10.76、9.93、5.96,P值均<0.05,二者治疗的临床差别在统计学上均具有意义。结论:恩替卡韦治疗乙肝的疗效显著优于拉夫米定。
OBJECTIVE: To compare the efficacy of entecavir and lamivudine in the treatment of hepatitis B and to find a better treatment for hepatitis B. Methods: 60 cases of hepatitis B patients admitted to our hospital were included in the study. Patients were divided into entecavir group and lamivudine group according to the random principle. The patients in lamivudine treatment group were given lamivudine orally on the basis of this treatment. The patients in entecavir treatment group were treated with entecavir orally on the basis of this study. The ALT returned to normal after 16 weeks, 32 weeks and 64 weeks in both groups Liver fibrosis index recovery and Child-Pugh liver function score grading, using spss15.0 statistical software to analyze the above data, a comprehensive evaluation of the treatment effect of two groups of patients. Results: After treatment for 16 weeks, 32 weeks and 64 weeks, the indexes of liver function improved obviously in both groups. However, the improvement of liver function in entecavir group was significantly better than that of lamivudine group. SPSS15.0 software analysis After χ2 test were 10.76,9.93,5.96, P values were <0.05, the clinical difference between the two treatments are statistically significant. Conclusion: The efficacy of entecavir in the treatment of hepatitis B is significantly better than lamivudine.